Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
IL-2 is an inducer of regulatory T cells (Treg), a population of lymphocytes that fail to
control the autoimmune destruction of beta-cells in patients with Type 1 Diabetes (T1D). The
investigators recently showed that low dose IL-2 is well tolerated in patients with an
autoimmune disease. The investigators aim to use IL-2 to induce/stimulate Treg in T1D
patients. This study will investigate the dose effect relationship of low dose IL-2 for Treg
induction such as to optimize the risk benefit ratio for this treatment in T1D. By Treg
induction, the investigators aim to protect the remaining/regenerating β-cells from
autoimmune destruction, thus improving or even curing T1D.